DTE Announces Appointment of Diego Areces as CEO
16.9.2021 08:00:00 EEST | Business Wire | Press release
The Board of DTE ehf. (DTE) (www.dte.ai), a leader in metals intelligence, is pleased to announce the appointment of Diego Areces as Chief Executive Officer.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210915006176/en/
Diego Areces, CEO of DTE (Photo: Business Wire)
Diego Areces, who joined DTE in 2020 after a long tenure at Schneider Electric, succeeds Karl Matthiasson, one of the Company's two founders, who steps into the role of Chief Financial Officer.
The changes reflect DTE's increased commercial focus and reorganization to accelerate its market expansion, as it continues to innovate around its unique elemental analysis LP-LIBS™ technology, advances its real-time and predictive metals intelligence platform to the next level, and launches its forthcoming Series B financing round. Diego Areces' mission will be to lead DTE through its growth phase, while Karl Matthiasson, in his new role as CFO, will focus on solidifying DTE's financial foundation, expanding its global presence and leading the next funding round.
“I'm very pleased to take on the CEO role to continue building on the success of DTE’s technological accomplishments,” commented Mr. Areces. “Our disruptive technology is poised to transform the metals market and the team has developed solid relationships with strategic customers, which collectively form the launch pad of DTE's market expansion. Our metals intelligence platform enabled by our unique elemental analysis technology allows us to deliver beneficial financial and environmental business outcomes to our customers. We see ourselves as significant contributors to a carbon-neutral future and digital transformation towards Industry 4.0 for the industries we serve. I want to thank both Karl and Sveinn, the co-founders and prior CEOs, for their achievements and the support that they have provided to my appointment.”
“We’re delighted to announce Diego’s leadership and are convinced that he is the right person to drive DTE going forward,” commented DTE co-founder and CEO Karl Matthiasson. “We look forward to the next phase of the Company’s evolution and will continue to build a larger, stronger team to deliver the value that we can achieve through unlocking the future of metals.”
Richard MacKellar, Managing Partner at Chrysalix Ventures and Chairman of the Board of DTE, commented, “Chrysalix is excited and supportive of the nomination of Diego Areces as DTE's CEO. We welcome Diego to this new role in the Company as we continue to drive DTE's growth to fulfill its potential in leading a market of new and better, greener, safer, more efficient metals through technological innovation and value-added solutions. I would also like to thank and acknowledge Karl for his outstanding leadership up to this point, which continues with the challenge of leading DTE's financing and next funding rounds.”
Find out more about DTE's metals intelligence solutions at www.dte.ai.
About DTE ehf.
DTE, Unlocking the Future of Metals™, is the leading innovator in real-time intelligence from liquid metals, serving customers across the metals production and manufacturing value chain through maximizing value, sustainability, safety, and efficiency for all stakeholders.
Our purpose is advancing human progress with greener, safer, more efficient, and more valuable metals, contributing to the 1.5-degree challenge while driving its digital transformation towards Industry 4.0 with the next generation of IIoT analysis technology. DTE provides tangible financial and environmental business outcomes from the plant floor to the business levels through valuable intelligence and predictive insights from liquid metals.
IREAS, DTE's unique, connected, real-time intelligence from liquid metals solution seamless integrated IT and OT, combining chemical composition analysis from molten metals based on Liquid-Phase Laser-Induced Breakdown Spectroscopy (LP-LIBS™) with an artificial intelligence-based analytics platform and digital metals intelligence services.
For more information, please visit www.dte.ai.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210915006176/en/
Contact information
DTE ehf.
Diego Areces, CEO
diego.areces@dte.ai
(+354) 698 0173
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 12:18:00 EEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 11:11:00 EEST | Press release
Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom